Dan Roden

July 1, 2020

VUMC-led network to focus on polygenic risk for common diseases

With the aid of a $75 million, five-year grant renewal, the Electronic Medical Records and Genomics Network (eMERGE) will venture beyond its current focus on monogenic disease to scoring research participants’ relative risk for complex heritable diseases such as cardiovascular disease, chronic kidney disease and type 2 diabetes.

By Paul Govern
June 12, 2020

Robotic technology speeds arrhythmia gene classification

Vanderbilt University Medical Center investigators have used high-throughput robotic technology to rapidly study and classify variations in a gene linked to heart rhythm disorders and cardiac conditions.

By Leigh MacMillan
Medical laboratory scientist Gladys Garrison, MT, MS, loads reagents to prepare DNA samples for analysis in the VUMC Molecular Diagnostics Lab.
April 30, 2020

PREDICT program expands, opens new Genomics Clinic

A new clinic opening at Vanderbilt University Medical Center will help doctors and patients choose the best drugs for their medical conditions based on the patients’ unique genetic makeup.

By Bill Snyder
January 9, 2020

Interim directors of Cardiovascular Medicine named

Dan Roden, MD, and Daniel Munoz, have been named interim directors of the Division of Cardiovascular Medicine at Vanderbilt University Medical Center.

By Matt Batcheldor
November 18, 2019

Roden wins Schottenstein Prize from Ohio State University

By Bill Snyder
Researchers on the NCI Moonshot grant focused on hereditary cancers include (front row, from left) Natasha Celaya-Cobbs, LPN, Georgia Wiesner, MD, Sarah Bland, MPH, MBA, (back row, from left) Trent Rosenbloom, MD, Josh Peterson, MD, MPH, and Marc Beller, PMP, BA.
November 14, 2019

NCI ‘Moonshot’ grant to boost hereditary cancer identification

VUMC is leading an initiative to establish a streamlined process for collection of family health histories that could set the stage for a standardized system to make the information easily accessible.

By Tom Wilemon
October 24, 2019

Article examines need for genotyping after stenting

Genotyping can improve outcomes in patients who require anti-platelet therapy following stent placement to open narrowed or blocked coronary arteries and prevent a heart attack.
By Bill Snyder
October 17, 2019

Peterson, Roden honored for translational medicine efforts

Josh Peterson, MD, MPH, and Dan Roden, MD, are among 10 leaders in clinical pharmacology and translational medicine recognized this week by the American Society for Clinical Pharmacology and Therapeutics.
By Bill Snyder
September 25, 2019

Study identifies targeted therapy’s cardiac risks

After a recent study showed that chronic lymphocytic leukemia patients who received ibrutinib as a frontline treatment had a 7% death rate, a new study offers a clearer picture on the reasons for the deaths.
By Tom Wilemon
May 22, 2019

Van Driest lands young investigator award from the American Society for Clinical Pharmacology and Therapeutics

Sara Van Driest, MD, PhD, assistant professor of Pediatrics and Medicine, recently received the 2019 Leon I. Goldberg Early Investigator Award from the American Society of Clinical Pharmacology and Therapeutics.
By Christina Echegaray
June 21, 2018

Roden’s circulatory diseases research honored

Jun. 21, 2018—Vanderbilt University’s Dan Roden, MD, internationally known for his contributions to understanding how genetic variation affects drug response, has been named a recipient of the 2018 Louis and Artur Lucian Award for Research in Circulatory Diseases by McGill University in Montreal, Canada.
By Bill Snyder
June 21, 2018

Roden’s circulatory diseases research honored

Vanderbilt University’s Dan Roden, MD, internationally known for his contributions to understanding how genetic variation affects drug response, has been named a recipient of the 2018 Louis and Artur Lucian Award for Research in Circulatory Diseases by McGill University in Montreal, Canada.
By Bill Snyder
June 14, 2018

VUMC joins research network to fight atrial fibrillation

Vanderbilt University Medical Center (VUMC) has been selected by the American Heart Association (AHA) to participate in a six-member research network to advance treatment and prevention of atrial fibrillation (AFib), an irregular heart rate that increases the risk of stroke and other heart-related complications.
By Bill Snyder